

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel: 0265-6637300

Email: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

Extract of Statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2023

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	30.06.2023	30.06.2022	31.03.2023
	Unaudited	Unaudited	Audited
Total Income from Operations	1,486.15	1,262.14	5,652.62
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	129.76	(67.38)	354.59
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	129.76	(67.38)	354.59
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	120.60	(65.88)	341.99
Total Comprehensive Income for the period	119.66	(60.58)	355.36
Equity Share Capital	39.31	39.31	39.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	6.14	(3.35)	17.40
Research and Development Expenses	118.59	261.05	721.84

Notes:

1.	Standalone details	Quarter Ended		Year Ended
		30.06.2023	30.06.2022	31.03.2023
		Unaudited	Unaudited	Audited
	Income from Operations	1,332.27	1,177.25	5,149.00
	Profit Before Tax	97.53	(49.39)	345.93
	Profit After Tax	97.53	(49.39)	346.73
	Research and Development Expenses	117.75	252.82	699.39

2. The above is an extract of the detailed format of the Unaudited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchange's website at www.nseindia.com and www.bseindia.com

For Alembic Pharmaceuticals Limited

Sd/-

Place: Vadodara

Date: 4th August, 2023
 Chirayu Amin
Chairman and CEO